

Renal cell carcinoma treatment: The search for the right strategy

Poster Session 58

Sunday, 26 March
15:45 - 17:15

Location: Room 7, Capital suite (level 3)

Chairs: S. Fernández-Pello Montes, Gijón (ES)
F. Porpiglia, Turin (IT)
I. Sinescu, Bucharest (RO)

Aims and objectives of this session

To discuss various aspects which impact the indication for RCC therapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 769 **Modified 5-item frailty index is associated with increased healthcare resource utilization following elective minimally invasive radical nephrectomy**
By: Xia L., Taylor B., [Guzzo T.](#)
Institutes:University of Pennsylvania, Perelman School of Medicine, Division of Urology, Dept. of Surgery, Philadelphia, United States of America
- 770 **Is a preoperative low ejection fraction a risk factor for complications and impaired survival in renal cancer patients who undergo surgery? Results from a propensity-score matching with non cardiopathic counterparts**
By: [Nini A.](#)¹, Larcher A.¹, Muttin F.¹, Zaffuto E.¹, Dell'Oglio P.¹, Ripa F.¹, Carezzi C.¹, La Croce G.¹, Oppizzi M.², Fragasso G.², Montorsi F.¹, Capitanio U.¹, Bertini R.¹
Institutes:¹IRCCS San Raffaele, Dept. of Urology, Division of Oncology/Unit of Urology, URI, Milan, Italy, ²IRCCS San Raffaele, Dept. of Cardiology, Milan, Italy
- 771 **The ability of three comorbidity indexes to predict postoperative mortality in renal cell carcinoma patients: The impending need of a new disease-specific index**
By: [Dell'Oglio P.](#), Larcher A., Muttin F., Fossati N., Nini A., Ripa F., La Croce G., Trevisani F., Carezzi C., Salonia A., Briganti A., Montorsi F., Bertini R., Capitanio U.
Institutes:IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy
- 772 **Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?**
By: Hamilton Z.¹, Larcher A.³, Lane B.², Capitanio U.³, Hassan A-E.¹, Berquist S.¹, Dufour C.¹, Beksac A.T.¹, Wan F.¹, Proudfoot J.¹, [Derweesh I.](#)¹, Montorsi F.³
Institutes:¹Moore's Cancer Center, Dept. of Urology, La Jolla, United States of America, ²Spectrum Health, Dept. of Urology, Grand Rapids, United States of America, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- 773 **Tumor size is associated with compensatory hypertrophy in the contralateral kidney before and after radical nephrectomy in patients with renal cell carcinoma**
By: [Park B.H.](#), Bae S.R., Lee Y.S., Kang S.H., Han C.H.
Institutes:Uijeongbu St. Mary's Hospital, Dept. of Urology, Uijeongbu-Si, South Korea
- 774 **Clinical application of calculated split renal volume using computed tomography-based renal volumetry after partial nephrectomy: Correlation with 99mTc-DMSA renal scan data**
By: Lee C.H., [Ku J.Y.](#), Ha H.K.
Institutes:Pusan National University Hospital, Dept. of Urology, Busan, South Korea

- 775 **Functional data as assessed by renal scintigraphy and volumetric assessment on CT-scan prior and after partial nephrectomy. Is there a correlation?**
By: Porpiglia F.¹, Bertolo R.¹, Amparore D.¹, Piramide F.¹, Checcucci E.¹, Angusti T.², Barrera M.³, Sardo D.³, Veltri A.³, Mele F.¹, Fiori C.¹
Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Luigi Hospital, Dept. of Nuclear Medicine, Turin, Italy, ³San Luigi Hospital, Dept. of Radiology, Turin, Italy
- 776 **Characterisation of solid renal tumours with magnetic resonance elastography (MRE) at 3T: Integrating biomechanical, morphological and functional assessment**
By: Prezzi D.¹, Neji R.², Stirling J.¹, Jeljeli S.¹, Verma H.³, O'Brien T.⁴, Challacombe B.⁴, Fernando A.⁴, Chandra A.⁶, Sinkus R.⁵, Goh V.¹
Institutes:¹King's College London, Dept. of Cancer Imaging, London, United Kingdom, ²Siemens Healthineers, Dept. of MR Research Collaborations, Frimley, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵King's College London, Dept. of Biomedical Engineering, London, United Kingdom, ⁶Guy's and St Thomas' NHS Foundation Trust, Dept. of Pathology, London, United Kingdom
- 777 **Discrimination of malignant and benign kidney tissue with 1064 nm dispersive Raman spectroscopy**
By: Haifler M.¹, Pence I.², Ristau B.¹, Greenberg R.¹, Chen D.¹, Smaldone M.¹, Kutikov A.¹, Viterbo R.¹, Uzzo R.¹, Zisman A.³, Mahadeven-Jensen A.², Patil C.⁴
Institutes:¹Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ²Vanderbilt University, Dept. of Biomedical Engineering, Nashville, United States of America, ³Assaf Harofe Medical Center, Dept. of Urology, Be'er Ya'akov, Israel, ⁴Temple University, Dept. of Biomedical Engineering, Philadelphia, United States of America
- 778 **Topographic distribution of sentinel lymph nodes in patients with renal tumours**
By: Kuusk T.¹, Grivas N.¹, Donswijk M.², Prevoo W.³, Horenblas S.¹, Bex A.¹
Institutes:¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands
- 779 **The effect of anatomical location of retroperitoneal lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma**
By: Nini A.¹, Larcher A.¹, Terrone C.², Volpe A.², Muttin F.¹, Ripa F.¹, Regis F.², Lucianò R.³, Briganti A.¹, Bertini R.¹, Montorsi F.¹, Capitanio U.¹
Institutes:¹IRCCS San Raffaele, Dept. of Urology, Division of Oncology, Milan, Italy, ²University Hospital Maggiore Della Carità, University of Piemonte Orientale, Dept. of Urology, Novara, Italy, ³IRCCS San Raffaele, Dept. of Pathology, Milan, Italy
- 780 **Lymph node dissection is not associated with increased 30-day complications among patients undergoing radical nephrectomy for renal cell carcinoma: A propensity-score based analysis**
By: Gershman B.¹, Moreira D.², Thompson R.H.³, Boorjian S.³, Lohse C.⁴, Costello B.⁵, Cheville J.⁶, Leibovich B.³
Institutes:¹Rhode Island Hospital And The Miriam Hospital, Dept. of Urology, Providence, United States of America, ²University of Illinois, Dept. of Urology, Chicago, United States of America, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Mayo Clinic, Health Sciences Research, Rochester, United States of America, ⁵Mayo Clinic, Dept. of Oncology, Rochester, United States of America, ⁶Mayo Clinic, Dept. of Pathology, Rochester, United States of America
- V14 **Laparoscopic inter-aorto-caval lymph-node dissection for RCC**
By: Bass R., Sidi A., Tsvivan A.
Institutes:E. Wolfson M. C., Dept. of Urologic Surgery, Holon, Israel